242 related articles for article (PubMed ID: 24034309)
1. Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States.
Frueh FW
Value Health; 2013; 16(6 Suppl):S27-31. PubMed ID: 24034309
[TBL] [Abstract][Full Text] [Related]
2. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.
O'Donnell JC
Value Health; 2013; 16(6 Suppl):S1-3. PubMed ID: 24034305
[TBL] [Abstract][Full Text] [Related]
3. Reflections on market access for personalized medicine: recommendations for Europe.
Payne K; Annemans L
Value Health; 2013; 16(6 Suppl):S32-8. PubMed ID: 24034310
[TBL] [Abstract][Full Text] [Related]
4. Melding regulatory, pharmaceutical industry, and U.S. payer perspectives on improving approaches to heterogeneity of treatment effect in research and practice.
Willke RJ; Crown W; Del Aguila M; Cziraky MJ; Khan ZM; Migliori R
Value Health; 2013; 16(6 Suppl):S10-5. PubMed ID: 24034306
[TBL] [Abstract][Full Text] [Related]
5. A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topics.
Neumann PJ; Saret CJ
Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):657-61. PubMed ID: 24138650
[TBL] [Abstract][Full Text] [Related]
6. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
[TBL] [Abstract][Full Text] [Related]
7. Personalized medicine policy challenges: measuring clinical utility at point of care.
van Rooij T; Wilson DM; Marsh S
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):289-95. PubMed ID: 22812553
[TBL] [Abstract][Full Text] [Related]
8. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
9. The application of economics concepts to stratified medicine--use of health economics data to support market access for stratified medicine interventions.
Fugel HJ; Nuijten M; Faulkner E
J Med Econ; 2014 May; 17(5):305-11. PubMed ID: 24654841
[TBL] [Abstract][Full Text] [Related]
10. Implementation of genomic medicine in a health care delivery system: a value proposition?
Wade JE; Ledbetter DH; Williams MS
Am J Med Genet C Semin Med Genet; 2014 Mar; 166C(1):112-6. PubMed ID: 24619641
[TBL] [Abstract][Full Text] [Related]
11. Tutorial on health economics and outcomes research in nutrition.
Philipson T; Linthicum MT; Snider JT
JPEN J Parenter Enteral Nutr; 2014 Nov; 38(2 Suppl):5S-16S. PubMed ID: 25239114
[TBL] [Abstract][Full Text] [Related]
12. [The origin of informed consent].
Mallardi V
Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
[TBL] [Abstract][Full Text] [Related]
13. The lag from FDA approval to published cost-utility evidence.
Chambers JD; Thorat T; Pyo J; Neumann PJ
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):399-402. PubMed ID: 25579324
[TBL] [Abstract][Full Text] [Related]
14. Personalized medicine and therapeutic decision-making in oncology: a commentary on key environmental issues.
Freeman RA
J Oncol Pharm Pract; 2011 Sep; 17(3):295-7. PubMed ID: 20551112
[No Abstract] [Full Text] [Related]
15. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
[TBL] [Abstract][Full Text] [Related]
16. Overcoming regulatory and economic challenges facing pharmacogenomics.
Cohen JP
N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
[TBL] [Abstract][Full Text] [Related]
17. Current methodological issues in the economic assessment of personalized medicine.
Annemans L; Redekop K; Payne K
Value Health; 2013; 16(6 Suppl):S20-6. PubMed ID: 24034308
[TBL] [Abstract][Full Text] [Related]
18. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
19. The Personalized Medicine Coalition: goals and strategies.
Abrahams E; Ginsburg GS; Silver M
Am J Pharmacogenomics; 2005; 5(6):345-55. PubMed ID: 16336000
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
